JAGUAR HEALTH, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.22 USD | -1.63% |
|
-8.86% | -53.54% |
| May. 30 | Top Premarket Gainers | MT |
| May. 29 | Jaguar Health Expands Out-licensing Agreement With Magdalena Biosciences | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 435,810 | 240,177 | 9,973 | 800.8 | 7.684 | 20.63 | - |
| Enterprise Value (EV) 1 | 435,814 | 240,177 | 9,973 | 800.8 | 7.684 | 20.63 | 20.63 |
| P/E ratio | -0.09 x | -0.82 x | -0.88 x | -0.18 x | -0.08 x | -0.78 x | -1 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 75,462 x | 25,592 x | 2,301 x | 67 x | - | 1.37 x | 0.91 x |
| EV / Revenue | 75,462 x | 25,592 x | 2,301 x | 67 x | - | 1.37 x | 0.91 x |
| EV / EBITDA | -19,315,902,881 x | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 40,302 | 21,829 | 2,131 | 2,048 | 846 | 4,889 | - |
| Reference price 2 | 10,814 | 11,003 | 4,680 | 391.1 | 9.084 | 4.220 | 4.220 |
| Announcement Date | 4/3/20 | 3/31/21 | 3/11/22 | 3/24/23 | 4/1/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 5.775 | 9.385 | 4.335 | 11.96 | - | 15.11 | 22.66 |
| EBITDA | -22.56 | - | - | - | - | - | - |
| EBIT 1 | -24.3 | -26.65 | -40.71 | -34.42 | - | -23.88 | -18.99 |
| Operating Margin | -420.75% | -283.93% | -939.05% | -287.85% | - | -158.04% | -83.8% |
| Earnings before Tax (EBT) 1 | -38.53 | -33.81 | -52.6 | -48.4 | - | -26.28 | -21.39 |
| Net income 1 | -44.73 | -38.65 | -52.6 | -47.45 | -41.3 | -26.28 | -21.39 |
| Net margin | -774.45% | -411.81% | -1,213.26% | -396.91% | - | -173.92% | -94.4% |
| EPS 2 | -121,635 | -13,500 | -5,310 | -2,171 | -107.4 | -5.400 | -4.200 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 4/3/20 | 3/31/21 | 3/11/22 | 3/24/23 | 4/1/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2.08 | 2.625 | 2.921 | 3.15 | 3.26 | - | 2.676 | 2.813 | 2.351 | 4.01 | 4.22 | 3.92 | 4.44 | 6.02 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -10.82 | -11.75 | -6.479 | -9.896 | -6.286 | - | -8.102 | -8.787 | -8.215 | -6.11 | -6.32 | -4.28 | -6.3 | -4.86 |
| Operating Margin | -520.29% | -447.77% | -221.81% | -314.16% | -192.82% | - | -302.77% | -312.37% | -349.43% | -152.37% | -149.76% | -109.18% | -141.89% | -80.73% |
| Earnings before Tax (EBT) 1 | -14.32 | -18.16 | -9.39 | -12.61 | -8.232 | - | -12.29 | -7.904 | -9.368 | -6.71 | -6.92 | -4.88 | -6.9 | -5.46 |
| Net income 1 | -14.31 | -17.99 | -9.367 | -12.52 | -7.581 | -12.2 | -12.15 | -7.778 | -9.226 | -6.71 | -6.92 | -4.88 | -6.9 | -5.46 |
| Net margin | -688.12% | -685.18% | -320.68% | -397.46% | -232.55% | - | -454.04% | -276.5% | -392.43% | -167.33% | -163.98% | -124.49% | -155.41% | -90.7% |
| EPS 2 | -1,395 | -1,800 | -540.0 | -540.0 | - | -143.4 | -41.40 | -22.80 | -3.600 | -1.200 | -1.200 | -1.200 | -1.200 | -1.200 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/11/22 | 5/10/22 | 8/22/22 | 11/14/22 | 3/24/23 | 5/15/23 | 8/14/23 | 11/14/23 | 5/14/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt | 3.73 | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | -0.1655 x | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | - | - | 0.01 | 0.08 | - | 0.01 | 0.01 |
| Capex / Sales | - | - | 0.14% | 0.64% | - | 0.07% | 0.04% |
| Announcement Date | 4/3/20 | 3/31/21 | 3/11/22 | 3/24/23 | 4/1/24 | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
4.22
USD
Average target price
36
USD
Spread / Average Target
+753.08%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -53.54% | 20.63M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- JAGX Stock
- Financials Jaguar Health, Inc.
